Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PIPE-791 Dose A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PIPE-791 Dose A | EXPERIMENTAL | - |
| PIPE-791 Dose B | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PIPE-791 Dose A | DRUG | Participants will receive a daily oral dose of PIPE-791 in tablet form |
| PIPE-791 Dose B | DRUG | Participants will receive a daily oral dose of PIPE-791 in tablet form |
| Placebo | DRUG | Participants will receive a daily oral dose of matching Placebo in tablet form |
Key Inclusion Criteria: * Male or female ≥ 40 years of age at the time of Randomization. * A diagnosis of IPF within 7 years prior to Screening, based on the 2022 ATS/ERS/JRS/ALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT consistent with usual intersti...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
PIPE-791 Dose A is an investigational small molecule being studied for idiopathic pulmonary fibrosis (IPF) and relapsing remitting multiple sclerosis (RRMS). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
PIPE-791 Dose A targets the lysophosphatidic acid receptor 1 (LPAR1). By modulating this receptor, the drug is being evaluated for its potential effects in treating idiopathic pulmonary fibrosis and relapsing remitting multiple sclerosis.
PIPE-791 Dose A is being developed by Contineum Therapeutics, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol CTNM.
PIPE-791 Dose A is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. Clinical trials are ongoing to evaluate its safety and efficacy in patients with idiopathic pulmonary fibrosis.
PIPE-791 Dose A is being studied in a Phase 2 trial (NCT07284459) for idiopathic pulmonary fibrosis, which is currently recruiting 324 participants across multiple countries. A separate Phase 2 trial (NCT06083753) for relapsing remitting multiple sclerosis has been completed.
PIPE-791 Dose A is a specific dose formulation of the investigational drug PIPE-791. The clinical trial NCT07284459 evaluates PIPE-791 in patients with idiopathic pulmonary fibrosis, and the completed trial NCT06083753 studied PIPE-307 in relapsing remitting multiple sclerosis.